Analysts Turn More Bullish on LifeStance Health Group (LFST) After Dual Price Target Hikes

We recently compiled a list of the 15 High Growth Mid-Cap Stocks to Buy. LifeStance Health Group, Inc. (NASDAQ:LFST) is among the high growth stocks.

TheFly reported on January 8 that KeyBanc analyst Steve Dechert increased the price target for LFST from $6.50 to $8.50, keeping an Overweight rating on the stock. KeyBanc described this period as a possible “year of inflection” for several firms it watches, with changes to estimates and values showing indications of stabilizing, following a difficult year for HCIT shares. The firm warned that competition and regulatory considerations may continue to put pressure on valuation multiples, but it expects ongoing positive momentum throughout the majority of its coverage.

On the same day, Canaccord analyst Richard Close increased the price target for LifeStance Health Group, Inc. (NASDAQ:LFST) from $8.00 to $9.00, maintaining a Buy rating on the stock. The firm noted that LFST might be somewhat protected from more general industry uncertainty and updated its model to take opportunities within a changing healthcare environment into consideration. The expansion of in-network access to care was also emphasized as a benefit of favorable payer policies.

LifeStance Health Group, Inc. (NASDAQ:LFST) is a U.S.‑based provider of outpatient mental health services, offering both in‑person and virtual care to children, adolescents, adults, and older adults. The company’s multidisciplinary clinicians deliver psychiatric evaluations, therapy (individual, family, group), medication management, and psychological testing for conditions like anxiety, depression, bipolar disorder, and PTSD.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.